InsiderDB

Lobbying disclosures · Lobbying report

BIIB: second_quarter 2026 lobbying report

Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. Intellectual property protections and enforcement. Biopharmaceutical patent policy. Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathwa

Follow BIIB
Became public
Jul 20, 2026, 5:22 PM EDT
Event / period date
Not stated
Collected
Nov 10, 2026, 2:18 PM EST

Why this is connected

Exact legal-name match: BIOGEN INC. (https://www.sec.gov/Archives/edgar/data/875045/).

Reported lobbying amounts

Income: $60,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/270f36db-1764-4e2a-958d-bbaf76169343/","filing_uuid":"270f36db-1764-4e2a-958d-bbaf76169343","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/270f36db-1764-4e2a-958d-bbaf76169343/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"William Minor, Partner","dt_posted":"2026-07-20T17:22:02-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"500 8th Street, NW","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":76855,"url":"https://lda.gov/api/v1/registrants/76855/","house_registrant_id":32113,"name":"DLA PIPER LLP (US)","description":"Law firm.","address_1":"500 8th Street, NW","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"WILLIAM MINOR","contact_telephone":"+1 202-799-4312","dt_updated":"2026-07-30T08:35:35.415773-04:00"},"client":{"id":67421,"url":"https://lda.gov/api/v1/clients/67421/","client_id":67421,"name":"BIOGEN, INC.","general_description":"Biotechnology company.","client_government_entity":null,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-06-01"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142803,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SORENSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145585,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"PORTMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152192,"prefix":null,"prefix_display":null,"first_name":"MAREN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Intellectual property protections and enforcement. Biopharmaceutical patent policy.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142803,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SORENSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145585,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"PORTMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152192,"prefix":null,"prefix_display":null,"first_name":"MAREN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to the 340B program.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142803,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SORENSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145585,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"PORTMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152192,"prefix":null,"prefix_display":null,"first_name":"MAREN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Issues related to rare disease and treatment. Drug pricing policy. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142803,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SORENSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145585,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"PORTMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152192,"prefix":null,"prefix_display":null,"first_name":"MAREN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to tax reform.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Trade-related public policy around tariffs and intellectual property.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142803,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SORENSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145585,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"PORTMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152192,"prefix":null,"prefix_display":null,"first_name":"MAREN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Congressional trading in BIIB

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.